Efficacy and Safety of Deucravacitinib in Adults with Alopecia Areata

JRCT ID: jRCT2031220610

Registered date:06/02/2023

Basic Information

• Recruitment status: Not Recruiting
• Health condition(s) or Problem(s) studied: Alopecia Areata
• Date of first enrollment: 06/02/2023
• Target sample size: 9
• Countries of recruitment: Australia,Japan,Canada,Japan,France,Japan,Germany,Japan,Poland,Japan,USA,Japan
• Study type: Interventional

Intervention(s)

Arm A: deucravacitinib
Arm B: deucravacitinib
Arm C: Placebo

Outcome(s)

Primary Outcome

SALT score
safety and tolerability

• Secondary Outcome: SALT score

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: <= 65age old
• Gender: Both

Include criteria

Documented clinical diagnosis of AA for at least 6 months
Alopecia Areata Investigator Global Assessment ( AA-IGA)
grade >- 3

Exclude criteria

Other active skin diseases affecting the scalp that in the opinion of the investigator may interfere with accurate assessment of SALT score
History or evidence of active infection and/or febrile illness
Any ongoing treatment known to affect hair growth

Related Information

• Primary Sponsor: Fuentes Duculan David
• Secondary ID(s): NCT05556265